Since the start of 2020, Moderna (NASDAQ: MRNA) stock is up an astounding 438%. And yet an exuberant announcement made on the pharmaceutical giant's research and development (R) day (Sept. 13) suggests that the best may be yet to come.

In the announcement, management celebrated the successful conclusion of the phase 3 trials of the company's flu vaccine. It also noted that it would soon submit the data for its respiratory syncytial virus (RSV) drug to regulators for their evaluation too. It also said that it would initiate another phase 3 trial of its personalized cancer vaccine program in collaboration with Merck. 

Those developments have a high chance of leading to more revenue in the near term. But management went even further and gave investors 15 other new reasons to be bullish about the stock. Let's dig deeper and see what those reasons are and what they mean for the stock's long-term success.

Continue reading

Source Fool.com